Phase II study of gefitinib in patients with advanced salivary gland cancers

• Published in: Head & neck Vol. 37; no. 5; pp. 644 - 649
• Main Authors: Jakob, John A., Kies, Merrill S., Glisson, Bonnie S., Kupferman, Michael E., Liu, Diane D., Lee, J. Jack, El-Naggar, Adel K., Gonzalez-Angulo, Ana M., Blumenschein Jr, George R.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.05.2015; Wiley Subscription Services, Inc
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - pathology; adenoid cystic carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Carcinoma, Adenoid Cystic - drug therapy; Carcinoma, Adenoid Cystic - mortality; Carcinoma, Adenoid Cystic - pathology; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness - pathology; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; non-adenoid cystic carcinoma; Prognosis; Quinazolines - therapeutic use; Remission Induction; response to therapy; salivary gland cancer; Salivary Gland Neoplasms - drug therapy; Salivary Gland Neoplasms - mortality; Salivary Gland Neoplasms - pathology; Survival Analysis; Treatment Outcome; gefitinib; salivary gland cancer; adenoid cystic carcinoma; response to therapy; non-adenoid cystic carcinoma
• ISSN: 1043-3074; 1097-0347
• DOI: 10.1002/hed.23647

Background The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. Methods We conducted a phase II study in adenoid cystic carcinoma (ACC) and non‐ACC. Gefitinib was administered 250 mg orally daily. The primary endpoint was tumor response. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), and disease control rates. EGFR and human epidermal growth factor receptor 2 (HER2) expression were evaluated and correlated with outcomes. Results Thirty‐seven patients were enrolled in this study, and 36 were evaluable (18 with ACC and 18 with non‐ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non‐ACC, respectively. The disease control rate at 8 weeks was higher in patients with ACC. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. Conclusion We did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002. © 2015 Wiley Periodicals, Inc. Head Neck 37: 644–649, 2015